Drug Profile
NGD 982
Alternative Names: NGD 98-2Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator Neurogen Corporation
- Developer Neurogen Corporation; sanofi-aventis
- Class Antidepressants; Anxiolytics
- Mechanism of Action Corticotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 09 Jan 2002 Preclinical development for Anxiety disorders in USA (unspecified route)
- 09 Jan 2002 Preclinical development for Depression in USA (unspecified route)